NOMURA HOLDINGS INC-SPON ADR (NMR) Stock Fundamental Analysis
USA - NYSE:NMR - US65535H2085 - ADR
7.1 USD
+0.03 (+0.42%)
7.1 USD
0 (0%)
We assign a fundamental rating of 3 out of 10 to NMR. NMR was compared to 237 industry peers in the Capital Markets industry. Both the profitability and financial health of NMR have multiple concerns. NMR has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
NMR had positive earnings in the past year.
In the past year NMR has reported a negative cash flow from operations.
Each year in the past 5 years NMR has been profitable.
In multiple years NMR reported negative operating cash flow during the last 5 years.
1.2 Ratios
NMR has a Return On Assets of 0.60%. This is in the lower half of the industry: NMR underperforms 69.62% of its industry peers.
The Return On Equity of NMR (9.82%) is comparable to the rest of the industry.
NMR has a Return On Invested Capital of 0.63%. This is in the lower half of the industry: NMR underperforms 69.62% of its industry peers.
NMR had an Average Return On Invested Capital over the past 3 years of 0.42%. This is significantly below the industry average of 7.63%.
The 3 year average ROIC (0.42%) for NMR is below the current ROIC(0.63%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | 9.82% | ||
| ROIC | 0.63% |
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.42%
ROIC(5y)0.41%
1.3 Margins
Looking at the Profit Margin, with a value of 7.19%, NMR is doing worse than 63.29% of the companies in the same industry.
In the last couple of years the Profit Margin of NMR has declined.
The Operating Margin of NMR (9.96%) is worse than 67.09% of its industry peers.
In the last couple of years the Operating Margin of NMR has declined.
NMR has a Gross Margin (39.95%) which is comparable to the rest of the industry.
NMR's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.96% | ||
| PM (TTM) | 7.19% | ||
| GM | 39.95% |
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
2. Health
2.1 Basic Checks
NMR has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, NMR has less shares outstanding
Compared to 1 year ago, NMR has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -0.27, we must say that NMR is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -0.27, NMR is not doing good in the industry: 78.90% of the companies in the same industry are doing better.
A Debt/Equity ratio of 10.44 is on the high side and indicates that NMR has dependencies on debt financing.
NMR's Debt to Equity ratio of 10.44 is on the low side compared to the rest of the industry. NMR is outperformed by 89.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.44 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.27 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
NMR has a Current Ratio of 0.22. This is a bad value and indicates that NMR is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.22, NMR is doing worse than 88.19% of the companies in the same industry.
NMR has a Quick Ratio of 0.22. This is a bad value and indicates that NMR is not financially healthy enough and could expect problems in meeting its short term obligations.
NMR has a worse Quick ratio (0.22) than 87.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.22 | ||
| Quick Ratio | 0.22 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 34.52% over the past year.
The Earnings Per Share has been growing by 10.96% on average over the past years. This is quite good.
NMR shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.94%.
The Revenue has been growing by 19.39% on average over the past years. This is quite good.
EPS 1Y (TTM)34.52%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%-6.73%
Revenue 1Y (TTM)13.94%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%-8.91%
3.2 Future
Based on estimates for the next years, NMR will show a small growth in Earnings Per Share. The EPS will grow by 2.33% on average per year.
NMR is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -6.12% yearly.
EPS Next Y6.54%
EPS Next 2Y1.02%
EPS Next 3Y2.33%
EPS Next 5YN/A
Revenue Next Year-18.6%
Revenue Next 2Y-9.83%
Revenue Next 3Y-6.12%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 8.35 indicates a reasonable valuation of NMR.
77.22% of the companies in the same industry are more expensive than NMR, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 25.83. NMR is valued rather cheaply when compared to this.
With a Price/Forward Earnings ratio of 8.95, the valuation of NMR can be described as very reasonable.
Based on the Price/Forward Earnings ratio, NMR is valued a bit cheaper than 77.22% of the companies in the same industry.
NMR's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 32.68.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.35 | ||
| Fwd PE | 8.95 |
4.2 Price Multiples
NMR's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. NMR is cheaper than 68.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 22.74 |
4.3 Compensation for Growth
NMR's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PEG (NY)1.28
PEG (5Y)0.76
EPS Next 2Y1.02%
EPS Next 3Y2.33%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 4.69%, NMR is a good candidate for dividend investing.
NMR's Dividend Yield is comparable with the industry average which is at 8.39.
Compared to an average S&P500 Dividend Yield of 2.39, NMR pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.69% |
5.2 History
The dividend of NMR is nicely growing with an annual growth rate of 15.59%!
NMR has paid a dividend for at least 10 years, which is a reliable track record.
The dividend of NMR decreased in the last 3 years.
Dividend Growth(5Y)15.59%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
33.03% of the earnings are spent on dividend by NMR. This is a low number and sustainable payout ratio.
NMR's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP33.03%
EPS Next 2Y1.02%
EPS Next 3Y2.33%
7.1
+0.03 (+0.42%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners41.49%
Inst Owner Change-0.63%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap20.83B
Revenue(TTM)4.74T
Net Income(TTM)340.74B
Analysts73.33
Price Target7.73 (8.87%)
Short Float %0.04%
Short Ratio2.36
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.69% |
Yearly Dividend0.26
Dividend Growth(5Y)15.59%
DP33.03%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)23.99%
Min EPS beat(2)-10.21%
Max EPS beat(2)58.19%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)11.08%
EPS NQ rev (1m)-0.19%
EPS NQ rev (3m)-0.19%
EPS NY rev (1m)0%
EPS NY rev (3m)1.84%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.35 | ||
| Fwd PE | 8.95 | ||
| P/S | 0.68 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.92 | ||
| P/tB | 0.94 | ||
| EV/EBITDA | 22.74 |
EPS(TTM)0.85
EY11.97%
EPS(NY)0.79
Fwd EY11.17%
FCF(TTM)-3.44
FCFYN/A
OCF(TTM)-1.51
OCFYN/A
SpS10.51
BVpS7.7
TBVpS7.54
PEG (NY)1.28
PEG (5Y)0.76
Graham Number12.14
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | 9.82% | ||
| ROCE | 1.65% | ||
| ROIC | 0.63% | ||
| ROICexc | 0.69% | ||
| ROICexgc | 0.7% | ||
| OM | 9.96% | ||
| PM (TTM) | 7.19% | ||
| GM | 39.95% | ||
| FCFM | N/A |
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.42%
ROIC(5y)0.41%
ROICexc(3y)0.46%
ROICexc(5y)0.45%
ROICexgc(3y)0.46%
ROICexgc(5y)0.46%
ROCE(3y)1.09%
ROCE(5y)1.09%
ROICexgc growth 3Y16.87%
ROICexgc growth 5Y8.04%
ROICexc growth 3Y16.9%
ROICexc growth 5Y8.08%
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
F-Score6
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.44 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 67.92 | ||
| Cap/Depr | 1410.99% | ||
| Cap/Sales | 18.37% | ||
| Interest Coverage | 0.16 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.22 | ||
| Quick Ratio | 0.22 | ||
| Altman-Z | -0.27 |
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)988.49%
Cap/Depr(5y)668.06%
Cap/Sales(3y)14.69%
Cap/Sales(5y)11.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.52%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%-6.73%
EPS Next Y6.54%
EPS Next 2Y1.02%
EPS Next 3Y2.33%
EPS Next 5YN/A
Revenue 1Y (TTM)13.94%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%-8.91%
Revenue Next Year-18.6%
Revenue Next 2Y-9.83%
Revenue Next 3Y-6.12%
Revenue Next 5YN/A
EBIT growth 1Y72.34%
EBIT growth 3Y27.7%
EBIT growth 5Y13.71%
EBIT Next Year23728.8%
EBIT Next 3Y524.46%
EBIT Next 5YN/A
FCF growth 1Y-122.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-883.38%
OCF growth 3YN/A
OCF growth 5YN/A
NOMURA HOLDINGS INC-SPON ADR / NMR FAQ
Can you provide the ChartMill fundamental rating for NOMURA HOLDINGS INC-SPON ADR?
ChartMill assigns a fundamental rating of 3 / 10 to NMR.
Can you provide the valuation status for NOMURA HOLDINGS INC-SPON ADR?
ChartMill assigns a valuation rating of 5 / 10 to NOMURA HOLDINGS INC-SPON ADR (NMR). This can be considered as Fairly Valued.
What is the profitability of NMR stock?
NOMURA HOLDINGS INC-SPON ADR (NMR) has a profitability rating of 2 / 10.
How financially healthy is NOMURA HOLDINGS INC-SPON ADR?
The financial health rating of NOMURA HOLDINGS INC-SPON ADR (NMR) is 1 / 10.
What is the expected EPS growth for NOMURA HOLDINGS INC-SPON ADR (NMR) stock?
The Earnings per Share (EPS) of NOMURA HOLDINGS INC-SPON ADR (NMR) is expected to grow by 6.54% in the next year.